Korean J Obstet Gynecol.  2006 Sep;49(9):1827-1837.

Tibolone and Gynecologic Cancer

Affiliations
  • 1Department of Obstetrics and Gynecology, College of Medicine, Chosun University, Gwangju, Korea. hjung@chosun.ac.kr

Abstract

Tibolone is a tissue-selective compound used for the treatment of climacteric symptoms and the prevention of osteoporosis in post-menopausal women. Tibolone does not increase mammographic density. Absolute numbers of women at increased risk for breast cancer are estimated to be low or absent with both tibolone and estrogen therapy (ET), and the risk with tibolone should be significantly lower than that with estrogen/ progesterone therapy (EPT). Tibolone might therefore be preferable to EPT in certain women who have not been hysterectomised. As tibolone rarely causes endometrial proliferation, no additional progestogen is required. It also has good tolerability, being associated with a low incidence of vaginal bleeding and of breast pain. Although the best evidence currently available for the effects of tibolone on breast and endometrial cancer is from the Million Women Study (MWS), the risks reported in this observational study are probably overestimated. Recent prospective trial data show, that the absolute increase in risk for breast and endometrial cancer is lower than reported in the MWS.

Keyword

Tibolone; Breast cancer; Endometrial cancer

MeSH Terms

Breast
Breast Neoplasms
Climacteric
Endometrial Neoplasms
Estrogens
Female
Humans
Incidence
Mastodynia
Observational Study
Osteoporosis
Progesterone
Uterine Hemorrhage
Estrogens
Progesterone
Full Text Links
  • KJOG
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr